HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA proposed OTC label reg would require "extensive" relabeling for cosmetic-drugs -- CTFA.

This article was originally published in The Rose Sheet

Executive Summary

FDA OTC DRUG LABELING REG WOULD REQUIRE "MOST EXTENSIVE" RELABELING EFFORT for the cosmetics industry in "recent memory," the Cosmetic, Fragrance and Toiletry Association said in an April 17 letter to FDA requesting a 120-day extension on the comment period for the proposed rule. The labeling reg "will affect every cosmetic-drug brand and every size of the product type sold in the United States," CTFA maintains.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel